Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab ( (GMAB) ) has provided an announcement.
Genmab, the Copenhagen-based biotech specializing in antibody medicines, reported on May 8, 2026 that Orbis Investment Management Limited has become a major shareholder. The company’s pipeline of late-stage antibody-based therapies and its existing portfolio of eight approved medicines underscore its growing role in oncology and serious disease treatment.
In a major shareholder announcement filed with U.S. regulators, Genmab disclosed that Orbis now controls voting rights to 3,166,357 Genmab shares, equal to 5.08% of the company’s share capital and voting rights as of May 8, 2026. The new ownership stake formalizes Orbis as a significant institutional investor, signaling continued international investor interest in Genmab’s growth prospects and strategic trajectory.
The most recent analyst rating on (GMAB) stock is a Hold with a $33.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company has built a broad portfolio of therapeutic formats, including bispecific antibodies, antibody–drug conjugates and immune-modulating antibodies, and powers eight approved antibody medicines worldwide.
Average Trading Volume: 1,652,226
Technical Sentiment Signal: Sell
Current Market Cap: $16.49B
See more data about GMAB stock on TipRanks’ Stock Analysis page.